Liquidia Corp
Liquidia Corp is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 4 upcoming events on record.
Liquidia Corp generates cash from operations, so a burn-based runway figure does not apply.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 13, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| February 15, 2027 | A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks | Trial Milestone | Phase 2 |
| May 15, 2027 | A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | Trial Milestone | Phase 4 |
| July 15, 2029 | A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD | Trial Milestone | Phase 3 |
Track LQDA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open LQDA in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.